Payment overview · 2025
General Payments
$692.80
17 reported records · 8 companies
Healthcare provider profile · identity verified
Lawrence A Alder, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · KERRVILLE, TX · NPI 1023027182
Verified facts
What the public records show
CMS Open Payments records show Lawrence A Alder, M.D. received $692.80 in general payments during 2025 across 17 reported records.
Inspire Medical Systems, Inc. accounted for 28.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CALQUENCE as an associated drug or biological on 8404 records involving 3935 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Calquence by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $195.92 | 28.3% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $195.13 | 28.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $113.59 | 16.4% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $57.15 | 8.2% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$38.27 | 5.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.22 | 5.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.81 | 4.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.71 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $692.80 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $195.92 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $195.13 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $170.08 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $170.08 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $79.60 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $79.60 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $57.15 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $57.15 | 3 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $38.27 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $37.22 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.99 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.81 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.81 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $25.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 46 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 172 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
63 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | CALQUENCE open payments reported associated product |
CMS Open Payments — General Payments 8404 supporting records · 3935 recipient NPIs · example record 1206131382 |
Calquence · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
172 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 633 | 169 |
| Atorvastatin Calcium | Atorvastatin Calcium | 385 | 125 |
| Losartan Potassium | Losartan Potassium | 348 | 109 |
| Lisinopril | Lisinopril | 288 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 279 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 264 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 261 | 79 |
| Gabapentin | Gabapentin | 236 | 74 |
| Omeprazole | Omeprazole | 218 | 67 |
| Montelukast Sodium | Montelukast Sodium | 178 | 56 |
| Trazodone Hcl | Trazodone Hcl | 174 | 50 |
| Ozempic | Semaglutide | 172 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 167 | 52 |
| Zolpidem Tartrate | Zolpidem Tartrate | 158 | 27 |
| Sertraline Hcl | Sertraline Hcl | 149 | 34 |
| Metformin Hcl | Metformin Hcl | 141 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 140 | 43 |
| Tramadol Hcl | Tramadol Hcl | 120 | 34 |
| Meloxicam | Meloxicam | 118 | 44 |
| Metformin Hcl Er | Metformin Hcl | 118 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 115 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 113 | 30 |
| Furosemide | Furosemide | 111 | 34 |
| Famotidine | Famotidine | 99 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 98 | 42 |
| Potassium Chloride | Potassium Chloride | 96 | 34 |
| Quetiapine Fumarate | Quetiapine Fumarate | 94 | 18 |
| Azithromycin | Azithromycin | 92 | 75 |
| Fenofibrate | Fenofibrate | 90 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 87 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 83 | 27 |
| Simvastatin | Simvastatin | 83 | 24 |
| Celecoxib | Celecoxib | 81 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 81 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 27 |
| Bupropion Hcl Sr | Bupropion Hcl | 78 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 78 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 75 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 74 | 15 |
| Eliquis | Apixaban | 70 | 16 |
| Clonazepam | Clonazepam | 69 | 17 |
| Mirtazapine | Mirtazapine | 69 | 15 |
| Methylprednisolone | Methylprednisolone | 68 | 60 |
| Allopurinol | Allopurinol | 67 | 23 |
| Synthroid | Levothyroxine Sodium | 63 | 18 |
| Carvedilol | Carvedilol | 61 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 60 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | 13 |
| Pregabalin | Pregabalin | 56 | 14 |
| Finasteride | Finasteride | 52 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 13 |
| Cephalexin | Cephalexin | 47 | 40 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 47 | 13 |
| Farxiga | Dapagliflozin Propanediol | 46 | 12 |
| Jardiance | Empagliflozin | 46 | 15 |
| Spironolactone | Spironolactone | 46 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | 13 |
| Mounjaro | Tirzepatide | 44 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 17 |
| Clonidine Hcl | Clonidine Hcl | 43 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 42 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | suppressed |
| Carisoprodol | Carisoprodol | 40 | suppressed |
| Fluconazole | Fluconazole | 40 | 26 |
| Buspirone Hcl | Buspirone Hcl | 39 | 14 |
| Lorazepam | Lorazepam | 39 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | 12 |
| Diazepam | Diazepam | 38 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 14 |
| Alprazolam | Alprazolam | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 36 | suppressed |
| Estradiol | Estradiol | 36 | 13 |
| Ezetimibe | Ezetimibe | 36 | 13 |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 18 |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Levofloxacin | Levofloxacin | 32 | 26 |
| Valsartan | Valsartan | 32 | suppressed |
| Mupirocin | Mupirocin | 31 | 18 |
| Valacyclovir | Valacyclovir Hcl | 31 | 11 |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 29 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 26 | 12 |
| Prednisone | Prednisone | 25 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | 14 |
| Terbinafine Hcl | Terbinafine Hcl | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 18 |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 14 |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 11 |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 14 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 11 |
| Calquence | Acalabrutinib Maleate | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Dupixent Syringe | Dupilumab | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Almotriptan Malate | Almotriptan Malate | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $692.80 · 17 records | Inspire Medical Systems, Inc. | AIRSUPRA, Auvelity, BREZTRI, FARXIGA, INSPIRE, INTELLIS ADAPTIVESTIM, MOUNJARO, Ozempic, QULIPTA, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error